Baha’a Jabali

Researcher

Last publication 2025 Last refreshed 2026-05-16

unknown

4 h-index 5 pubs 109 cited

Biography and Research Information

OverviewAI-generated summary

Baha’a Jabali's research focuses on the discovery and development of novel kinase inhibitors, particularly for cancer treatment. His work has led to the identification of compounds targeting specific pathways involved in tumor growth and proliferation. He has published research on macrocyclic kinase inhibitors, exploring strategies to limit conformational flexibility for improved targeting of the kinome.

Jabali's recent publications include the discovery of an orally active selective aurora kinase B inhibitor, N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide. He has also investigated pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors. His scholarship metrics include an h-index of 4, with 5 total publications and 104 total citations. Jabali collaborates with researchers at the University of Arkansas for Medical Sciences, including Brendan Frett and Baku Acharya.

Metrics

  • h-index: 4
  • Publications: 5
  • Citations: 109

Selected Publications

  • Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
    6 citations DOI OpenAlex
  • Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
    3 citations DOI OpenAlex
  • Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)
    14 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

22 Collaborators 9 Institutions 4 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics